| Hazard Information | Back Directory | [Uses]
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes[1][2]. | [in vivo]
Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia[1]. | Animal Model: | Male Swiss mice with diabetes[1] | | Dosage: | 5 U/kg | | Administration: | Subcutaneous injection; 5 U/kg once daily for 30 days | | Result: | Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes. |
| [References]
[1] Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219. DOI:10.32725/jab.2021.025
[2] Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul DOI:10.1186/s12933-016-0410-9 |
|
| Company Name: |
Twochem Co.Ltd
|
| Tel: |
021-021-58111628 15800915896 |
| Website: |
www.twochem.com |
|